source
- Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.…
- Scaling delivery is key for CAR T therapies to succeed in autoimmune diseasesBiopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, the…